Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management

British Journal of Dermatology

Volumn 177, Issue 1, 2017, Pages 47-62

  Saunte, D M ^a   Mrowietz, U ^b   Puig, L ^c   Zachariae, C ^d  

^a ZEALAND UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BRODALUMAB; ETANERCEPT; INTERLEUKIN 17; IXEKIZUMAB; PLACEBO; SECUKINUMAB; USTEKINUMAB; IL17A PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

CANDIDA; ESOPHAGUS CANDIDIASIS; GENITAL CANDIDIASIS; HUMAN; INCIDENCE; META ANALYSIS; MUCOCUTANEOUS CANDIDIASIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THRUSH; VAGINA CANDIDIASIS; ANTAGONISTS AND INHIBITORS; CANDIDIASIS; CLINICAL TRIAL (TOPIC); COMPLICATION; IMMUNOTHERAPY; OPPORTUNISTIC INFECTION;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; CANDIDIASIS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-17; OPPORTUNISTIC INFECTIONS; PSORIASIS;

EID: 85020111766     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15015     Document Type: Review

References (51)

1. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
2. Yiu ZZ, Griffiths CE. Interleukin 17-A inhibition in the treatment of psoriasis. Expert Rev Clin Immunol 2016; 12:1–4.
3. Ling Y, Puel A. IL-17 and infections. Actas Dermosifiliogr 2014; 105 (Suppl.):34–40.
4. Ahn CS, Dothard EH, Garner ML et al. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol 2015; 73:420–8.
5. Salt E, Wiggins AT, Rayens MK et al. Risk factors for targeted fungal and mycobacterial infections in patients taking tumor necrosis factor inhibitors. Arthritis Rheumatol 2016; 68:597–603.
6. Ruhnke M, Rickerts V, Cornely OA et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 2011; 54:279–310.
7. Bedair AA, Darwazeh AMG, Al-Aboosi MM. Oral Candida colonization and candidiasis in patients with psoriasis. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114:610–5.
8. Picciani BLS, Michalski-Santos B, Carneiro S et al. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. J Am Acad Dermatol 2013; 68:986–91.
9. Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther 2012; 14:217.
10. Thaçi D, Blauvelt A, Reich K et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015; 73:400–9.
11. Papp K, Menter A, Strober B et al. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2015; 72:e1.
12. Gottlieb AB, Langley RG, Philipp S et al. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. J Drugs Dermatol 2015; 14:821–33.
13. Ohtsuki M, Morita A, Abe M et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 2014; 41:1039–46.
14. Mease PJ, Genovese MC, Mutebi A et al. Improvement in psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory with brodalumab treatment in patients with psoriatic arthritis. J Rheumatol 2016; 43:343–9.
15. Papp KA, Reich K, Paul C et al. A prospective phase 3, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175:273–86.
16. Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373:1318–28.
17. Mrowietz U, Leonardi CL, Girolomoni G et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015; 73:e1.
18. Thaçi D, Humeniuk J, Frambach Y et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol 2015; 173:777–87.
19. Paul C, Lacour J-P, Tedremets L et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 2015; 29:1082–90.
20. Blauvelt A, Prinz JC, Gottlieb AB et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015; 172:484–93.
21. Mease PJ, McInnes IB, Kirkham B et al. Secukinumab Inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015; 373:1329–39.
22. McInnes IB, Mease PJ, Kirkham B et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386:1137–46.
23. Rich P, Sigurgeirsson B, Thaci D et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168:402–11.
24. van der Heijde D, Landewé RB, Mease PJ et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol 2016; 68:1914–21.
25. Imafuku S, Honma M, Okubo Y et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol 2016; 43:1011–7.
26. Kavanaugh A, McInnes IB, Mease PJ et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol 2016; 43:1713–7.
27. McInnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73:349–56.
28. Papp K, Leonardi C, Menter A et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 2014; 71:e3.
29. Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci 2015; 81:44–52.
30. Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181–9.
31. Mease PJ, Genovese MC, Greenwald MW et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014; 370:2295–306.
32. Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190–9.
33. Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375:345–56.
34. Gordon KB, Leonardi CL, Lebwohl M et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 2014; 71:1176–82.
35. Saeki H, Nakagawa H, Ishii T et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2015; 29:1148–55.
36. Langley RG, Rich P, Menter A et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2015; 29:1763–70.
37. van de Veerdonk FL, Plantinga TS, Hoischen A et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011; 365:54–61.
38. Liu L, Okada S, Kong X-F et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011; 208:1635–48.
39. Conti HR, Gaffen SL. IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol 2015; 195:780–8.
40. Plato A, Willment JA, Brown GD. C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways. Int Rev Immunol 2013; 32:134–56.
41. Whibley N, Jaycox JR, Reid D et al. Delinking CARD9 and IL-17: CARD9 protects against Candida tropicalis infection through a TNF-α-dependent, IL-17-independent mechanism. J Immunol 2015; 195:3781–92.
42. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9:556–67.
43. Taheri Sarvtin M, Shokohi T, Hajheydari Z et al. Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis. Int J Dermatol 2014; 53:e555–60.
44. Armstrong AW, Bukhalo M, Blauvelt A. A clinician's guide to the diagnosis and treatment of candidiasis in patients with psoriasis. Am J Clin Dermatol 2016; 17:329–36.
45. Griffiths CEM, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386:541–51.
46. Yamasaki K, Nakagawa H, Kubo Y et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol 2017; 176:741–51.
47. Chen SC, Sorrell TC, Chang CC et al. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern Med J 2014; 44:1315–32.
48. Saunte DML, Hald M, Lindskov R et al. Guidelines for superficielle svampeinfektioner. Available at: http://www.dds.nu/wp-content/uploads/2012/08/Guidelines-for-superficielle-svampeinfektioner_version-2.pdf (last accessed 19 April 2017).
49. Arendrup MC, Cuenca-Estrella M, Lass-Flörl CHW. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Update 2013; 16:81–95.
50. Pappas PG, Kauffman CA, Andes DR et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1–50.
51. Lortholary O, Petrikkos G, Akova M et al. ECSMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 2012; 18(Suppl. 7):68–77.